170 results
SC14D9C
EX-2.1
CTIC
CTI BioPharma Corp
10 May 23
Written communication relating to third party tender offer
1:30pm
), firm, society or other enterprise, association, organization or entity.
Environmental Law. “Environmental Law” shall mean any federal, state, local
8-K
EX-2.1
CTIC
CTI BioPharma Corp
10 May 23
Tender and Support Agreement
8:05am
), firm, society or other enterprise, association, organization or entity.
Environmental Law. “Environmental Law” shall mean any federal, state, local
8-K
EX-99.1
CTIC
CTI BioPharma Corp
7 Nov 22
CTI BioPharma Reports Third Quarter 2022 Financial Results
4:07pm
Accomplishments and Updates
Abstract accepted for oral presentation at the American Society of Hematology (ASH) 2022 Annual Meeting and Exposition … of pacritinib presented at the Society of Hematologic Oncology (SOHO) 2022 Annual Meeting demonstrated pacritinib as a more potent inhibitor of ACVR1
8-K
EX-99.1
CTIC
CTI BioPharma Corp
8 Aug 22
CTI BioPharma Reports Second Quarter 2022 Financial Results
4:08pm
thrombocytopenia.
Data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating the safety profile of pacritinib 200 mg
8-K
EX-99.1
CTIC
CTI BioPharma Corp
12 May 22
CTI BioPharma Reports First Quarter 2022 Financial Results
4:07pm
abstract at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7, 2022, in Chicago and virtually:
◦Abstract Title
8-K
EX-99.1
qgsgdemg9njv2
10 Nov 20
CTI BioPharma Reports Third Quarter 2020 Financial Results
4:15pm
8-K
EX-99.1
8xb9iljc5f hg
12 Mar 20
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results
4:10pm
8-K
EX-10.1
ouf37
27 Feb 19
Entry into a Material Definitive Agreement
12:00am
424B5
54lx2qqlz nhv
1 Nov 18
Prospectus supplement for primary offering
4:26pm